Small, Dense HDL Particles Exert Potent Protection of Atherogenic LDL Against Oxidative Stress

Objectives—The relationship of the structural and functional heterogeneity of HDL particles to protection of LDL against oxidative stress is indeterminate. Methods and Results—HDL subfractions of defined physicochemical properties were isolated by density gradient ultracentrifugation from normolipidemic human serum (n=8), and their capacity to protect LDL from oxidation was evaluated. Under mild oxidative stress induced by AAPH or Cu(II), HDL subfractions (at equal cholesterol or protein concentration or equal particle number) significantly decreased LDL oxidation rate (−20% to −85%) in the propagation phase (234 nm), which was prolonged by up to 82% with decreased maximal diene formation. Antioxidative activity of HDL subfractions increased with increment in density, as follows: HDL2b<HDL2a<HDL3a<HDL3b<HDL3c (confirmed by thiobarbituric acid–reactive substance content and LDL electrophoretic mobility). Concordantly, antioxidative activity of small HDL prepared by FPLC was significantly higher (+56%) than that of large HDL. Antioxidative action of HDL subfractions was primarily associated with inactivation of LDL lipid hydroperoxides. The potent protective activity of small HDL could not be accounted for exclusively by enzymatic activities (PON1, platelet-activating factor acetylhydrolase, and lecithin-cholesterol acyltransferase). Conclusions—Small, dense HDL exhibit potent antioxidant activity, which may arise from synergy in inactivation of oxidized LDL lipids by enzymatic and nonenzymatic mechanisms, in part reflecting distinct intrinsic physicochemical properties.

[1]  E. Bruckert,et al.  Atherogenic, dense low-density lipoproteins. Pathophysiology and new therapeutic approaches. , 1998, European heart journal.

[2]  G. Francis,et al.  High density lipoprotein oxidation: in vitro susceptibility and potential in vivo consequences. , 2000, Biochimica et biophysica acta.

[3]  J. Gamble,et al.  Factors influencing the ability of HDL to inhibit expression of vascular cell adhesion molecule-1 in endothelial cells. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[4]  G. Assmann,et al.  Physiological role and clinical relevance of high‐density lipoprotein subclasses , 1994, Current opinion in lipidology.

[5]  R. Stocker,et al.  High density lipoprotein is the major carrier of lipid hydroperoxides in human blood plasma from fasting donors. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[6]  A. Tselepis,et al.  Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase. , 2002, Atherosclerosis. Supplements.

[7]  Jonathan D. Smith,et al.  Apolipoprotein E allele–specific antioxidant activity and effects on cytotoxicity by oxidative insults and β–amyloid peptides , 1996, Nature Genetics.

[8]  P. Durrington,et al.  Paraoxonase and Atherosclerosis , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[9]  D. Shih,et al.  The role of high-density lipoproteins in oxidation and inflammation. , 2001, Trends in cardiovascular medicine.

[10]  A. Nègre-Salvayre,et al.  Mildly oxidized LDL particle subspecies are distinct in their capacity to induce apoptosis in endothelial cells: role of lipid hydroperoxides , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[11]  J P Kane,et al.  Binding of transition metals by apolipoprotein A-I-containing plasma lipoproteins: inhibition of oxidation of low density lipoproteins. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[12]  D. Stengel,et al.  Effect of overexpression of human apo A-I in C57BL/6 and C57BL/6 apo E-deficient mice on 2 lipoprotein-associated enzymes, platelet-activating factor acetylhydrolase and paraoxonase. Comparison of adenovirus-mediated human apo A-I gene transfer and human apo A-I transgenesis. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[13]  S. Reddy,et al.  Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1. , 2000, Journal of lipid research.

[14]  J. Heinecke,et al.  Mechanisms for oxidizing low-density lipoprotein. Insights from patterns of oxidation products in the artery wall and from mouse models of atherosclerosis. , 2001, Trends in cardiovascular medicine.

[15]  R. Krauss,et al.  Dissociable and nondissociable forms of platelet-activating factor acetylhydrolase in human plasma LDL: implications for LDL oxidative susceptibility. , 1999, Biochimica et biophysica acta.

[16]  Z. Huang,et al.  Mechanism of high-density lipoprotein subfractions inhibiting copper-catalyzed oxidation of low-density lipoprotein. , 1998, Clinical biochemistry.

[17]  D. Steinberg,et al.  The oxidative modification hypothesis of atherosclerosis: does it hold for humans? , 2001, Trends in cardiovascular medicine.

[18]  G. Fonarow,et al.  formation of , 2022 .

[19]  C. Furlong,et al.  Apolipoprotein J is associated with paraoxonase in human plasma. , 1994, Biochemistry.

[20]  S. Biasioli,et al.  HDL3-related decreased serum paraoxonase (PON) activity in uremic patients: comparison with the PON1 allele polymorphism. , 2002, Clinica chimica acta; international journal of clinical chemistry.

[21]  James W. Anderson,et al.  Decreased protection by HDL from poorly controlled type 2 diabetic subjects against LDL oxidation may Be due to the abnormal composition of HDL. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[22]  G. Getz,et al.  Serum paraoxonase: effect of the apolipoprotein composition of HDL and the acute phase response. , 2003, Journal of lipid research.

[23]  J. S. Owen,et al.  Evidence for a paraoxonase-independent inhibition of low-density lipoprotein oxidation by high-density lipoprotein. , 1997, Atherosclerosis.

[24]  J. Dallongeville,et al.  Apolipoprotein A-I-containing lipoproteins and atherosclerosis , 1995, Current opinion in lipidology.

[25]  P. Lesnik,et al.  PAF-acether-degrading acetylhydrolase in plasma LDL is inactivated by copper- and cell-mediated oxidation. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[26]  J. Wittes,et al.  Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. , 2001, JAMA.

[27]  B. Engelmann,et al.  Inhibition of peroxyl radical-mediated lipid oxidation by plasmalogen phospholipids and alpha-tocopherol. , 1999, Free radical biology & medicine.

[28]  A. Scanu,et al.  In vitro mass: activity distribution of lecithin--cholesterol acyltransferase among human plasma lipoproteins. , 1982, Atherosclerosis.

[29]  D. Stengel,et al.  Antioxidant properties of HDL in transgenic mice overexpressing human apolipoprotein A-II. , 2002, Journal of lipid research.

[30]  J. Ribalta,et al.  Antioxidative and Antiatherosclerotic Effects of Human Apolipoprotein A-IV in Apolipoprotein E-Deficient Mice , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[31]  E. Schnitzer,et al.  The effect of albumin on copper-induced LDL oxidation. , 1997, Biochimica et biophysica acta.

[32]  J. Holtzman,et al.  Physiologic concentrations of homocysteine inhibit the human plasma GSH peroxidase that reduces organic hydroperoxides. , 2000, The Journal of laboratory and clinical medicine.

[33]  M. Chapman,et al.  Plasma LDL and HDL subspecies are heterogenous in particle content of tocopherols and oxygenated and hydrocarbon carotenoids. Relevance to oxidative resistance and atherogenesis. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[34]  W. J. Johnson,et al.  Effects of Acceptor Particle Size on the Efflux of Cellular Free Cholesterol (*) , 1995, The Journal of Biological Chemistry.

[35]  T. Fujinami,et al.  HDL3 exerts more powerful anti-oxidative, protective effects against copper-catalyzed LDL oxidation than HDL2. , 1997, Clinical biochemistry.

[36]  J. Goudevenos,et al.  Altered distribution of platelet-activating factor- acetylhydrolase activity between LDL and HDL as a function of the severity of hypercholesterolemia. , 2002, Journal of lipid research.

[37]  G. Lewis,et al.  HDL metabolism in hypertriglyceridemic states: an overview. , 1999, Clinica chimica acta; international journal of clinical chemistry.

[38]  D. Lichtenberg,et al.  Kinetics of lipid peroxidation in mixtures of HDL and LDL, mutual effects. , 2001, Free radical biology & medicine.

[39]  M. Couturier,et al.  Cholesteryl ester hydroperoxide lability is a key feature of the oxidative susceptibility of small, dense LDL. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[40]  S. Dhanjil,et al.  High-density lipoprotein composition and paraoxonase activity in Type I diabetes. , 2001, Clinical science.

[41]  B. La Du,et al.  Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. , 1999, Free radical biology & medicine.

[42]  Ming Liu,et al.  Novel Function of Lecithin-Cholesterol Acyltransferase , 1997, The Journal of Biological Chemistry.

[43]  S. Goldstein,et al.  A density gradient ultracentrifugal procedure for the isolation of the major lipoprotein classes from human serum. , 1981, Journal of lipid research.